"Best CRO" Award Recognizes Accelovance's Support of Vaccine Development

Rockville, MD-May 4, 2009-Accelovance, a privately held vaccine-focused clinical research company, announced today it received the Vaccine Industry Excellence (ViE) award as "Best Contract Research Organization” (CRO) at the 2009 World Vaccine Congress, held recently in
Chantilly, VA.

The ViE awards were established to generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry. The “Best CRO” award is designed to highlight the importance of contract research services within the
vaccine industry. It identifies Accelovance as best-in-class for services that advance vaccine development.

“There is obviously tremendous pride with this award. It reflects our commitment to excellence and focus on the niche market of vaccines,” commented Steve Trevisan, President and CEO of Accelovance. “This award recognizes how we have served clients, both large and small, across
all stages of clinical development by providing solutions to their needs or challenges. We will continue to focus on our clients and our mission of bringing innovation, operational efficiencies and high quality performance at multiple levels through our offering of CRO, Clinical Sites, Patient
Recruitment and Clinical Call Center services.”

A panel of international judges reviews nominations to determine each year’s recipients of the ViE awards. In 2008, Accelovance was a finalist in the same category of “Best CRO.” Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost-effective clinical studies. Accelovance offers seven (7) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor’s needs.

Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company’s website at www.accelovance.com.